Nothing Special   »   [go: up one dir, main page]

EP2934478B1 - Polyoléfines contenant du silicium dans des applications de soin personnel - Google Patents

Polyoléfines contenant du silicium dans des applications de soin personnel Download PDF

Info

Publication number
EP2934478B1
EP2934478B1 EP13799471.1A EP13799471A EP2934478B1 EP 2934478 B1 EP2934478 B1 EP 2934478B1 EP 13799471 A EP13799471 A EP 13799471A EP 2934478 B1 EP2934478 B1 EP 2934478B1
Authority
EP
European Patent Office
Prior art keywords
silane
personal care
weight
units derived
polyolefin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP13799471.1A
Other languages
German (de)
English (en)
Other versions
EP2934478A2 (fr
Inventor
Thomas P. Clark
Vivek KALIHARI
Nahrain E. Kamber
Xiaodong Lu
Ying O'connor
Thomas H. Peterson
Curtis Schwartz
Qichun Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Global Technologies LLC
Rohm and Haas Co
Original Assignee
Dow Global Technologies LLC
Rohm and Haas Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies LLC, Rohm and Haas Co filed Critical Dow Global Technologies LLC
Publication of EP2934478A2 publication Critical patent/EP2934478A2/fr
Application granted granted Critical
Publication of EP2934478B1 publication Critical patent/EP2934478B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8105Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
    • A61K8/8111Homopolymers or copolymers of aliphatic olefines, e.g. polyethylene, polyisobutene; Compositions of derivatives of such polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Definitions

  • the present invention relates to personal care formulations having improved sensory feel, while also being non-tacky and easily spreadable on skin. These improved personal care formulations contain silane functionalized polyolefins.
  • the present invention also relates to methods for improving the sensory feel of personal care formulations by including silane functionalized polyolefins in the formulations, as well as for treating skin by applying the aforesaid formulations.
  • Silicone elastomers were developed as alternatives to cationic quats and silicone oils and are currently considered one of the best sensory modifiers used in skin care formulations. Due to the unique structure of silicone elastomers (i.e., loose-crosslinked silicone polymer swollen in silicone oil) and large particle size, it has a skin feel unlike any of the silicone fluids or cationic quats. Their feel has been described as “velvety”, “powdery”, “smooth,” and “cushion feel”. Also, their skin feel can be modified by controlling the amount of solvent in the formula, and therefore the degree of swelling. In general, the irregular shapes of these soft elastomer particles give a distinctly different feel on the skin.
  • silicone elastomers are high cost and limited compatibility with other solvents.
  • silicone elastomers tend to be limited high end skincare products, with the aforesaid shortcomings prohibiting their broad application for the mass market.
  • the absence of technology for producing new materials and formulations with performance comparable to silicone oils limits entry of new personal care products into high-volume and high demand personal care markets.
  • WO2011034836A1 describes a process for making melt-shaped articles, e.g., wire and cable components, by a process in 3ww which the starting materials for the stable thermoplastic composition comprising silane functionalized polyolefin polymers (in particular vinyltrimethoxysilane-grafted polyethylene (PE-g-VTMS)) are combined and reacted in situ during the melt-forming process, thereby avoiding the need for post-shaping external heat or moisture.
  • silane functionalized polyolefin polymers in particular vinyltrimethoxysilane-grafted polyethylene (PE-g-VTMS)
  • PE-g-VTMS vinyltrimethoxysilane-grafted polyethylene
  • U.S. Patent Application Publication No. US2009/0214455A1 discloses a composition for coating keratin materials which is formed by applying two compounds, at least one of which is a silicone compound and which are capable of reacting with one another.
  • the resulting compositions have better adhesion to keratin and better biocompatibility, i.e., improved feel and low odor.
  • JP 2008174571A discloses cosmetic compounds containing silicone-modified olefin waxes manufactured by addition reaction of olefin waxes with Si-H bond-containing silicones, in the presence of catalysts, wherein the olefin waxes comprise ethylene-diene copolymers and ethylene-C 3-12 -olefin-diene copolymers. These cosmetics were shown to have good spreadability, water repellency, use feel, storage stability, and give softness, smoothness, emollient effect, and luster to skin and hair.
  • US Patent No. 7,863,361 discloses a silicone-based composition comprising combination of silicone polymer and alkyltrisiloxane for personal care applications, which provides a silicone composition with lower solids, while maintaining a desirable range of viscosity.
  • US 4834972 discloses products for the personal care industry formulated with gels comprising a telomer-copolymer of ethylene and a silane, and a solvent.
  • the present invention addresses the problem of providing personal care formulations having improved sensory feel, while retaining other desired characteristics including spreadability and non-tacky feel on skin, by using variants of the above-mentioned silicone-modified polyolefins.
  • Such elastomeric polymers can be swelled or dissolved in the carrier fluids to produce formulations having a soft, silky, and smooth feel and are easily spreadable and non-tacky on skin.
  • Such formulations can provide better cost-to-treat sensory performance and improved formulation compatibility, making them economically and technically viable skin care alternatives for mass market products.
  • the present invention provides a personal care formulation comprising: (A) at least one silane functionalized polyolefin; and (B) a carrier.
  • the silane functionalized polyolefin (A) comprises polymerized units derived from: (i) 50 to 99.9 % by weight of polymerized units derived from one or more olefin monomers; and (ii) 0.1 to 50 % by weight of polymerized units derived from at least one polymerizable silane selected from the group consisting of vinyl trimethoxy silane, vinyl triethoxy silane, vinyl triacetoxy silane, gamma-(meth)acryloxy propyl trimethoxy silane and mixtures thereof, and wherein said at least one silane functionalized polyolefin (A) is crosslinked.
  • weight percent is based on the total weight of the silane-containing polyolefin and the weight percents of components (a) and (b) totals 100%.
  • the at least one silane functionalized polyolefin (A) comprises polymerized units derived from: (i) 97 to 99.5 % by weight of polymerized units derived from said least one C 2 -C 40 olefin monomer; and (ii) 0.5 to 3 % by weight of polymerized units derived from said least one polymerizable silane.
  • the silane functionalized polyolefin (A) comprises at least 50 % by weight of polymerized units derived from polyethylene, based on the total weight of the silane functionalized polyolefin (A).
  • the polymerizable silane is selected from the group consisting of vinyl trialkoxy silanes.
  • the carrier may be selected from the group consisting of: aromatic or aliphatic hydrocarbons, alcohols, aldehydes, ketones, amines, esters, oleochemically derived oils, ethers, glycols, glycol ethers, silicone oils, water, and combinations thereof.
  • the personal care formulation may further comprise one or more other ingredients selected from emollients, thickeners, solvents, colorants and surfactants.
  • the present invention also provides a method for treating the body which comprises applying the aforesaid personal care formulation externally to the body.
  • the present invention also provides a method for improving the sensory feel of personal care formulations which comprises including in the formulation at least one silane functionalized polyolefin (A) as described above.
  • the present invention provides a personal care formulation comprising a silane functionalized polyolefin and a solvent.
  • the silane functionalized polyolefin comprises polymerized units derived from one or more polyolefin monomers, such as one or more C 2 -C 40 olefins, or one or more C 2 -C 20 olefins, or one or more C 2 -C 10 olefins, or preferably one or more C 2 -C 8 olefins and at least one polymerizable silane.
  • the silane units may have been copolymerized with the olefins or subsequently grafted onto the polyolefin polymer to form the silane functionalized polyolefin.
  • the personal care formulation may further comprise one or more polyolefins different from the silane functionalized polyoelfins.
  • a method for improving the sensory feel of personal care formulations comprises including at least one silane functionalized polyolefin in the personal care formulation.
  • the present invention also provides a method for treating the body which comprises applying one or more of the above-described personal care formulations externally to the body.
  • ambient conditions and like terms means temperature, pressure and humidity of the surrounding area or environment of an article.
  • the ambient conditions of a typical office building or laboratory include a temperature of 23 °C and atmospheric pressure.
  • the numerical ranges in this disclosure are approximate, and thus may include values outside of the range unless otherwise indicated. Numerical ranges include all values from and including the lower and the upper values, in increments of one unit, provided that there is a separation of at least two units between any lower value and any higher value. As an example, if a compositional, physical or other property, such as, for example, molecular weight, viscosity, melt index, etc., is from 100 to 1,000, it is intended that all individual values, such as 100, 101, 102, etc., and sub ranges, such as 100 to 144, 155 to 170, 197 to 200, etc., are expressly enumerated.
  • a compositional, physical or other property such as, for example, molecular weight, viscosity, melt index, etc.
  • Polymer means a compound prepared by reacting (i.e., polymerizing) monomers, as well as oligomers and other polymers, whether of the same or a different types.
  • the generic term polymer thus embraces the term “homopolymer,” usually employed to refer to polymers prepared from only one type of monomer, and the terms “copolymer” and “interpolymer” which are polymers prepared by the polymerization of two or more different types of monomers, oligomers and/or polymers.
  • oligomers are simply small polymers, i.e., having a smaller number (i.e., 2-100,000) of repeated monomer units.
  • Olefins also referred to herein as alkenes or alkene monomers, are unsaturated chemical compounds containing at least one carbon-to-carbon double bond, the simplest of which conform to the general formula C n H 2n , where n is a positive non-zero integer.
  • a polymer comprising polymerized units derived from a polyolefin means that the polymer was formed from the polymerization reaction of at least one olefin monomer.
  • Polyolefins are polymers containing units derived from at least one type of olefin, typically a C 2 -C 10 olefin, such as ethylene, propylene, butylene, pentene, hexane, etc.
  • polyethylene is a polymer which contains units derived from ethylene monomers, and typically comprises at least 50 mole percent (50 mol%) units derived from ethylene.
  • polypropylene contains units derived from propylene monomers, typically at least 50 mol% propylene.
  • Blend means a blend of two or more polymers. Such a blend may or may not be miscible. Such a blend may or may not be phase separated. Such a blend may or may not contain one or more domain configurations, as determined from transmission electron spectroscopy, light scattering, x-ray scattering, and any other method known in the art.
  • Crosslinked means that the polymer has been subjected or exposed to a treatment (e.g., heat, presence of free radicals, light, exposure to water, etc.) which induced reaction and bonding between functional groups of the polymer and other functional groups within the same polymer or the functional groups of other functionalized polymers. Furthermore, a polymer need not have all, or even most, of its functional groups reacted with other functional groups, to be considered a "crosslinked” polymer. In fact, a polymer having only a very small portion, such as at least 5 mole %, of the functional groups reacted or bonded is considered crosslinked, for purposes of the present invention.
  • Crosslinkable means that the polymer has not yet been crosslinked or bonded, but does comprise functional groups which will cause or promote crosslinking upon subjection or exposure to such treatment (e.g., exposure to water, heating, etc.).
  • composition means a physical mixture or blend of two or more components.
  • a reaction composition prior to reaction or polymerization, is a physical mixture which includes at least one ethylene polymer, at least one vinyl silane, and at least one free radical initiator.
  • a typical formulation might include a solvent or carrier, and any desired additives such as lubricants, fillers, anti-oxidants, and the like.
  • personal care formulation means a mixture or blend of compounds or ingredients which is suitable for external application to the body to deliver therapeutic or cosmetic compounds to skin and hair and may be in the form of creams, gels, lotions, liquids, sprays, powders, mousses and foams. Personal care formulations may be of the leave-on or rinse-off types, depending on their purpose and the types of compounds to be delivered.
  • Specific products made from personal care formulations include, without limitation: deodorants, antiperspirants, and antiperspirant/deodorants; shaving creams or gels; skin lotions, moisturizers, and toners; bath and shower soaps, gels and lotions; cleansing products; hair care products such as shampoos, conditioners, mousses, styling gels, hair sprays, hair dyes, hair color products, hair bleaches, waving products, hair straighteners, hair frizz control, and hair volumizers; manicure products such as nail polish, nail polish remover, nail creams and lotions, cuticle softeners; protective creams and sprays such as sunscreen, insect repellent and anti-aging products, color cosmetics such as lipsticks, foundations, face powders, eye liners, eye shadows, blushes, makeup, mascaras, as delivery vehicles for fragrances, as well as drug delivery systems for topical application of medicinal compositions to the skin.
  • suitable personal care formulation ingredients include, for example, emollients, moisturizers, humectants, pigments, including pearlescent pigments such as, for example, bismuth oxychloride and titanium dioxide-coated mica, colorants, fragrances, biocides, preservatives, antioxidants, anti-microbial agents, anti-fungal agents, antiperspirant agents, exfoliants, hormones, enzymes, medicinal compounds, vitamins, salts, electrolytes, alcohols, polyols, ultraviolet radiation absorbing or blocking agents, botanical extracts, surfactants, silicone oils, organic oils, waxes, film formers, thickening agents such as, for example, fumed silica or hydrated silica, particulate fillers, such as for example, talc, kaolin, starch, modified starch, mica, nylon, clay, such as, for example, bentonite and organo-modified clays, and combinations thereof.
  • pearlescent pigments such as, for example, bismuth oxychloride and titanium dioxide
  • the personal care formulations comprising a silane functionalized polyolefin according to the present invention will now be described in detail. These personal care formulations have improved sensory feel, i.e., softness and smoothness, as well as the degrees of other characteristics desired by consumers, including spreadability, non-tackiness and absorption, compared to personal care formulations containing conventional sensory enhancers such as cationic quats and silicone oils.
  • silane functionalized polyolefin means a polyolefin polymer having silane functionality. They may be random or block polymers, and linear or branched+.
  • the silane functionality can be the result of either polymerizing one or more olefin monomers with at least one polymerizable silane, or grafting at least one polymerizable silane onto an existing polyolefin as described in further detail hereinafter. Grafting is typically understood by persons of ordinary skill in the art to mean that the additional monomer or functional group is bonded directly to the backbone of the existing polymer.
  • silanes effectively copolymerize with one or more olefin monomers, or graft to, or crosslink with, a pre-existing polyolefin, to synthesize the silane functionalized polyolefin suitable for inclusion in the personal care formulation of the present invention.
  • Preferred silanes are the unsaturated alkoxy silanes can be grafted onto the polymer or copolymerized in-reactor with other monomers (such as ethylene and acrylates). These silanes and their method of preparation are more fully described in U.S. Pat. No. 5,266,627 to Meverden, et al. Vinyl trimethoxy silane (VTMS), vinyl triethoxy silane (VTES), vinyl triacetoxy silane, gamma-(meth)acryloxy propyl trimethoxy silane and mixtures of these silanes are the vinyl silanes for use in this invention.
  • VTMS Vinyl trimethoxy silane
  • VTES vinyl triethoxy silane
  • VTES vinyl triacetoxy silane
  • gamma-(meth)acryloxy propyl trimethoxy silane and mixtures of these silanes are the vinyl silanes for use in this invention.
  • the amount of polymerizable silane used in the practice of the present invention can vary widely depending upon the nature of the polymer, the silane, the processing or reactor conditions, the grafting or copolymerization efficiency, the ultimate application, and similar factors, but typically at least 0.1, preferably at least 0.5, weight percent is used. Considerations of convenience and economy are two of the principal limitations on the maximum amount of silane crosslinker used in the practice of this invention, and typically the maximum amount of silane crosslinker does not exceed 50, preferably it does not exceed 15, weight percent, based on the total amount of silane-containing polyolefin.
  • Olefin monomers suitable for polymerizing with at least one polymerizable silane to form the silane functionalized polyolefins useful in the present invention may be ⁇ -olefins, such as C 2-20 , or C 2-10 , or even C 2-8 ⁇ -olefins. Moreover, they may be linear, branched or cyclic ⁇ -olefins.
  • Non-limiting examples of linear and branched ⁇ -olefins include ethylene, propene, 1-butene, 4-methyl-1-pentene, 1-hexene, 1-octene, 1-decene, 1-dodecene, 1-tetradecene, 1-hexadecene, and 1-octadecene.
  • the ⁇ -olefins may also contain a cyclic structure such as cyclohexane or cyclopentane, resulting in an ⁇ -olefin such as 3-cyclohexyl-1-propene (allyl cyclohexane) and vinyl cyclohexane.
  • cyclic olefins such as norbornene and related olefins, particularly 5-ethylidene-2-norbornene
  • ⁇ -olefins suitable for inclusion in the polyolefins, which otherwise comprise at least 50 weight percent acyclic C 2-20 ⁇ -olefins.
  • styrene and its related olefins are ⁇ -olefins for purposes of this invention.
  • the olefin monomers used to prepare the silane functionalized polyolefins may be of a single type, resulting in a silane functionalized homopolymer.
  • more than one type of olefin monomer may be reacted with the polymerizable silane to form suitable silane functionalized polyolefins.
  • the silane functionalized polyolefin may be synthesized from olefin monomers and vinyl silanes using conventional polyolefin polymerization technology, such as high-pressure, Ziegler-Natta, metallocene, constrained geometry catalysis, among others well known to persons of ordinary skill in the relevant art.
  • polymerization may be performed using a high pressure process.
  • the silane functionalized polyolefin may be prepared using a mono- or bis-cyclopentadienyl, indenyl, or fluorenyl transition metal (preferably Group 4) catalysts or constrained geometry catalysts (CGC) in combination with an activator, in a solution, slurry, or gas phase polymerization process.
  • copolymerization of vinyl trialkoxy silanes with one or more olefin monomers may be done in a high-pressure reactor that is used in the manufacture of ethylene homopolymers and copolymers with vinyl acetate and acrylates.
  • such polymerization may be accomplished at conditions well-known in the art, such as without limitation, at temperatures from 0 to 250 °C, preferably from 30 to 200 °C, and pressures from atmospheric to 10,000 atmospheres (1013 megaPascal (MPa)). Suspension, solution, slurry, gas phase, solid state powder polymerization or other process conditions may be employed, if desired.
  • the catalyst can be supported or unsupported, and the composition of the support can vary widely.
  • Silica, alumina or a polymer especially poly(tetrafluoroethylene) or a polyolefin
  • a support is employed when the catalyst is used in a gas phase polymerization process.
  • the support is preferably employed in an amount sufficient to provide a weight ratio of catalyst (based on metal) to support within a range of from 1:100,000 to 1:10, more preferably from 1:50,000 to 1:20, and most preferably from 1:10,000 to 1:30.
  • the molar ratio of catalyst to polymerizable compounds employed is from 10-12:1 to 10-1:1, more preferably from 10 -9 :1 to 10 -5 :1.
  • Inert liquids may serve as suitable solvents for polymerization.
  • suitable solvents for polymerization include straight and branched-chain hydrocarbons such as isobutane, butane, pentane, hexane, heptane, octane, and mixtures thereof; cyclic and alicyclic hydrocarbons such as cyclohexane, cycloheptane, methylcyclohexane, methylcycloheptane, and mixtures thereof; perfluorinated hydrocarbons such as perfluorinated C 4-10 alkanes; and aromatic and alkyl-substituted aromatic compounds such as benzene, toluene, xylene, and ethylbenzene. Selection of a suitable solvent for polymerization is well within the ability of persons of ordinary skill in the relevant art.
  • silane functionalized polyolefins suitable for inclusion in the personal care formulations of the present invention may be synthesized by grafting at least one vinyl silane onto an existing polyolefin polymer.
  • the existing polyolefin polymers comprise polymerized units derived from one or more olefin monomers, such as one or more C 2-20 ⁇ -olefins, or one or more C 2-10 ⁇ -olefins, or even C 2-8 ⁇ -olefins.
  • the polyolefins may be homopolymers comprising only one type of olefin monomer, or they may be copolymers comprising two or more types of olefin monomers.
  • the preferred class of vinyl silanes for grafting onto exiting polyolefins is the vinyl trialkoxy silanes.
  • Grafting the silane onto existing polyolefins may be accomplished by any conventional method, typically in the presence of a free radical initiator, e.g., peroxides and azo compounds, or by ionizing radiation, etc.
  • Organic initiators are preferred, such as any one of the organic peroxide initiators, for example, dicumyl peroxide, di-tert-butyl peroxide, t-butyl perbenzoate, benzoyl peroxide, cumene hydroperoxide, t-butyl peroctoate, methyl ethyl ketone peroxide, 2,5-dimethyl-2,5-di(t-butyl peroxy)hexane, lauryl peroxide, and tert-butyl peracetate.
  • a suitable azo compound is 2,2-azobisisobutyronitrile.
  • the amount of initiator can vary, but it is typically present in an amount of at least 0.04, preferably at least 0.06, parts per hundred resin (phr). Typically, the initiator does not exceed 0.15, preferably it does not exceed about 0.10, phr.
  • the weight ratio of silane crosslinker to initiator also can vary widely, but the typical crosslinker:initiator weight ratio is between 10:1 to 500:1, preferably between 18:1 and 250:1. As used in parts per hundred resin or phr, "resin" means the olefinic polymer.
  • one particularly suitable method is blending the two with the initiator in the first stage of a reactor extruder, such as a Buss kneader.
  • the grafting conditions can vary, but the melt temperatures are typically between 160 and 260 °C., preferably between 190 and 230 °C., depending upon the residence time and the half life of the initiator.
  • polystyrene foams While various kinds of polyolefins may be used to synthesize grafted silane functionalized polyolefin suitable for the present invention, the present invention will now be described with polyethylene homo- or co-polymers as the polyolefin. As will be recognized by persons of ordinary skill in the relevant art, use of other types of polyolefins are equally acceptable for the present invention, and much of the following detailed discussion will be instructional and analogously applicable to other types of polyelofins when used for the present invention.
  • ethylene homopolymers may be used with the aforesaid grafting process to synthesize silane functionalized polyolefins suitable for use in the present invention.
  • ethylene/ ⁇ -olefin copolymers may be used having an ethylene content of at least 50 wt % and an ⁇ -olefin content of at least about 15, preferably at least about 20 and even more preferably at least about 25, wt %, based on the total weight of the copolymer.
  • These copolymers typically have an ⁇ -olefin content of less than about 50, preferably less than about 45, more preferably less than about 40 and even more preferably less than about 35, wt % based on the total weight of the copolymer.
  • the ⁇ -olefin content is measured by 13 C nuclear magnetic resonance (NMR) spectroscopy using the procedure described in Randall (Rev. Macromol. Chem. Phys., C29 (2&3 )).
  • Illustrative ethylene copolymers include ethylene/propylene, ethylene/butene, ethylene/1-hexene, ethylene/1-octene, ethylene/styrene, and the like.
  • Illustrative terpolymers include ethylene/propylene/1-octene, ethylene/propylene/butene, ethylene/butene/1-octene, ethylene/propylene/diene monomer (EPDM) and ethylene/butene/styrene.
  • the copolymers can be random or block.
  • the ethylene-based polymers used in the practice of this invention can be used alone or in combination with one or more other ethylene-based polymers, e.g., a blend of two or more ethylene polymers that differ from one another by monomer composition and content, catalytic method of preparation, etc. If the ethylene-based polymer is a blend of two or more ethylene polymers, then the ethylene polymer can be blended by any in-reactor or post-reactor process.
  • ethylene polymers made with high pressure processes include (but are not limited to) low density polyethylene (LDPE), ethylene silane reactor copolymer (such as SiLINK.RTM. made by The Dow Chemical Company), ethylene vinyl acetate copolymer (EVA), ethylene ethyl acrylate copolymer (EEA), and ethylene silane acrylate terpolymers.
  • LDPE low density polyethylene
  • ethylene silane reactor copolymer such as SiLINK.RTM. made by The Dow Chemical Company
  • EVA ethylene vinyl acetate copolymer
  • EOA ethylene ethyl acrylate copolymer
  • ethylene silane acrylate terpolymers examples include (but are not limited to) low density polyethylene (LDPE), ethylene silane reactor copolymer (such as SiLINK.RTM. made by The Dow Chemical Company), ethylene vinyl acetate copolymer (EVA), ethylene ethyl acrylate copolymer (EEA), and ethylene si
  • VLDPE very low density polyethylene
  • FLEXOMER ethylene/1-hexene polyethylene made by The Dow Chemical Company homogeneously branched, linear ethylene/.alpha.-olefin copolymers (
  • the more preferred ethylene polymers are the homogeneously branched linear and substantially linear ethylene copolymers.
  • the substantially linear ethylene copolymers are especially preferred, and are more fully described in U.S. Pat. Nos. 5,272,236 , 5,278,272 and 5,986,028 .
  • the resulting silane functionalized polyolefin may be combined with a carrier, and optional other ingredients, to produce a personal care formulation having soft, silky, and smooth feel and are easily spreadable and non-tacky on the skin.
  • Suitable carriers include, for example without limitation, aromatic or aliphatic hydrocarbons, alcohols, aldehydes, ketones, amines, esters, oleochemically derived oils, i.e., sunflower oil, ethers, glycols, glycol ethers, or silicone oils, or water.
  • the silane functionalized polyolefins When combined with such carriers, the silane functionalized polyolefins can be swelled or dissolved in the carrier, or even made into dispersions in water. Products containing the resulting personal care formulations deliver a soft, silky, and smooth feel and are easily spreadable and non-tacky on the skin. It is expected that these products will provide better cost-to-treat sensory performance and improved formulation compatibility in comparison to currently used, but more expensive, silicone elastomers.
  • the personal care formulation of the present invention may be in the form of a powder, liquid, pellet, bead, oil gel, oil paste, or an aqueous dispersion. It may be combined with other skin care ingredients, such as emollients (hydrocarbon oils, esters, natural oils, silicones), waxes, sensory modifiers, rheology modifiers, humectants (glycerin, etc), sunscreen actives, natural ingredients, bio-actives, colorants, hard particles, emulsifiers, solubilizers, and surfactants.
  • the amount of crosslinked silane-modified polyolefin included therein is typically 1 to 60, preferably 2 to 20 % by weight, based on the total weight of the personal care formulation.
  • the amount of crosslinked silane-modified polyolefin included therein is typically 0.1 to 60, preferably 1 to 40 % by weight, based on the total weight of the personal care formulation.
  • the amount of crosslinked silane-modified polyolefin included therein is typically 0.1 to 90, preferably 0.5 to 15 % by weight, based on the total weight of the personal care formulation.
  • a 1L kettle reactor was placed AFFINITY GA1950 (28.1 g) and ENGAGE-g-VTES (8.88 g). To the jar was added 322 mL of hexadecane to produce a 12.5 wt% solution. The reactor was fitted with an overhead stirrer, a nitrogen inlet (slow purge) and reflux condenser. A heating mantle was used to heat the stirred suspension to 180°C. After maintaining the homogeneous solution at 180°C for 1 hour, silanol-terminated PDMS (6.0 mL, 0.375 equiv relative to contained VTMS) was added via syringe. Stirring and heating was continued for a period of 90 minutes, after which the reactor contents were poured into a large jar and allowed to cool to ambient temperature producing a smooth gel.
  • silanol-terminated PDMS 6.0 mL, 0.375 equiv relative to contained VTMS
  • a suitable size vessel add in Phase I water, start mixing at moderator speed; sprinkle Xanthan Gum into water while mixing, mix until all hydrates and free of particles; add Glycerin to batch, heat to 75-80°C while mixing;
  • Phase II ingredients In a separate suitable size vessel, combine Phase II ingredients; for the control formulation, pre-mix Permethyl 101A, Affinity GA 1950 and Engage 7447 EL as indicated in Comparative Example I, before combining with other Phase II ingredients; heat Phase II mixture to 75-80°C with agitation until a uniform translucent solution is achieved;
  • Phase II add Phase II into Phase I with mixing at moderate to fast speed; mix until a uniform emulsion is achieved; turn off heat, air cool the batch while mixing;
  • Phase III When temperature is below 35°C, add Phase III into batch, mix until uniform; adjust pH with Citric Acid (50% solution) to pH5.5-6.5.
  • the in-vitro sensory evaluation of above-described sample skin care lotions was done by friction analysis using an automated tribometer.
  • the friction samples were made by drawing down thin films ( ⁇ 10 grams per square meter) of the skin care lotion on black lenetta plastic sheets using an automated coater.
  • the friction measurements were done on a tribometer, where a steel ball (3/8"diameter) is dragged over a coating at a fixed velocity (1 mm/sec) and constant normal load, and the lateral friction force is measured. Two measurements were performed for each normal load to conform the reproducibility.
  • the normal force (40-80 gm) was specifically chosen to broadly cover the force a person would put on their skin while applying the lotion.
  • the Figure demonstrates the in-vitro sensory test performance of skin care lotions comprising: Crosslinked silane-modified polyolefin via H 2 0 (Formulation B), Crosslinked silicone-modified polyolefin via PDMS (Formulation A), and Non-crosslinked polyolefin (Control) .
  • the normal force applied to the sample surface is plotted on the horizontal axis and the corresponding measured dynamic friction force is plotted on the vertical axis.
  • the higher friction force corresponds to higher drag a person would feel while applying the lotion on their skin.
  • One expects a higher drag force if a lotion is tacky and/or if a lotion is hard to spread.
  • the dynamic friction force captures both these factors and hence, a non-tacky and easy to spread skin care lotion should exhibit lower friction forces.
  • the plot shows that the lotions containing crosslinked polyolefins (crosslinked either by water or functionalized silicone) exhibit lower friction force than the non-crosslinked polyolefin at multiple normal loads.
  • the lower friction force indicates that the crosslinked polyolefin samples are less tacky, more smooth/less abrasive, and easier to spread than the non-crosslinked polyolefin lotion sample.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (9)

  1. Une formulation de soins personnels comprenant :
    (A) au moins une polyoléfine à fonctionnalité silane comprenant des unités polymérisées dérivées de :
    (i) 50 à 99,9 % en poids d'unités polymérisées dérivées d'un ou de plusieurs monomères oléfiniques ; et
    (ii) 0,1 à 50 % en poids d'unités polymérisées dérivées d'au moins un silane polymérisable sélectionné dans le groupe constitué de vinyltriméthoxysilane, de vinyltriéthoxysilane, de vinyltriacétoxysilane, de gamma-méthacryloxypropyltriméthoxysilane et de mélanges de ceux-ci ;
    et le pourcentage en poids étant rapporté au poids total de ladite polyoléfine contenant un silane et les pourcentages en poids des constituants (i) et (ii) faisant un total de 100 % ; et
    (B) un support ;
    dans laquelle ladite au moins une polyoléfine à fonctionnalité silane (A) est réticulée.
  2. La formulation de soins personnels de la revendication 1, dans laquelle ladite au moins une polyoléfine à fonctionnalité silane (A) comprend des unités polymérisées dérivées de :
    (i) 97 à 99,5 % en poids d'unités polymérisées dérivées dudit au moins un monomère oléfinique en C2 à C40 ; et
    (ii) 0,5 à 3 % en poids d'unités polymérisées dérivées dudit au moins un silane polymérisable.
  3. La formulation de soins personnels de la revendication 1, dans laquelle lesdits un ou plusieurs monomères oléfiniques sont un monomère oléfinique en C2 à C40.
  4. La formulation de soins personnels de la revendication 1, dans laquelle ladite polyoléfine à fonctionnalité silane (A) comprend au moins 50 % en poids d'unités polymérisées dérivées de polyéthylène, rapporté au poids total de la polyoléfine à fonctionnalité silane (A).
  5. La formulation de soins personnels de la revendication 4, dans laquelle ladite polyoléfine (A) comprend au moins 90 % en poids de polyéthylène.
  6. La formulation de soins personnels de la revendication 1, dans laquelle ledit support est sélectionné dans le groupe constitué : d'hydrocarbures aromatiques ou aliphatiques, d'alcools, d'aldéhydes, de cétones, d'amines, d'esters, d'huiles dérivées oléochimiquement, d'éthers, de glycols, d'éthers de glycol, d'huiles de silicone, d'eau, et de combinaisons de ceux-ci.
  7. La formulation de soins personnels de la revendication 1, comprenant en outre un ou plusieurs autres ingrédients sélectionnés parmi des émollients, des épaississants, des solvants, des colorants et des tensioactifs.
  8. Une méthode pour traiter le corps qui comprend l'application de la formulation de soins personnels de la revendication 1 de façon externe au corps.
  9. Une méthode pour améliorer le toucher sensoriel de formulations de soins personnels qui comprend le fait d'inclure dans ladite formulation (A) au moins une polyoléfine à fonctionnalité silane qui comprend des unités polymérisées dérivées de :
    (i) 50 à 99,9 % en poids d'unités polymérisées dérivées d'un ou de plusieurs monomères oléfiniques ; et
    (ii) 0,1 à 50 % en poids d'unités polymérisées dérivées d'au moins un silane polymérisable sélectionné dans le groupe constitué de vinyltriméthoxysilane, de vinyltriéthoxysilane, de vinyltriacétoxysilane, de gamma-(méth)acryloxy propyl triméthoxysilane et de mélanges de ceux-ci ;
    et le pourcentage en poids étant rapporté au poids total de ladite polyoléfine contenant un silane et les pourcentages en poids des constituants (i) et (ii) font un total de 100 % ; et
    (B) un support ;
    et dans laquelle ladite au moins une polyoléfine à fonctionnalité silane (A) est réticulée.
EP13799471.1A 2012-12-19 2013-11-22 Polyoléfines contenant du silicium dans des applications de soin personnel Not-in-force EP2934478B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261739452P 2012-12-19 2012-12-19
PCT/US2013/071403 WO2014099256A2 (fr) 2012-12-19 2013-11-22 Polyoléfines contenant du silicium dans des applications de soin personnel

Publications (2)

Publication Number Publication Date
EP2934478A2 EP2934478A2 (fr) 2015-10-28
EP2934478B1 true EP2934478B1 (fr) 2018-03-28

Family

ID=49709861

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13799471.1A Not-in-force EP2934478B1 (fr) 2012-12-19 2013-11-22 Polyoléfines contenant du silicium dans des applications de soin personnel

Country Status (6)

Country Link
US (2) US20160184210A1 (fr)
EP (1) EP2934478B1 (fr)
JP (1) JP6357484B2 (fr)
CN (1) CN105025877B (fr)
BR (1) BR112015012520B8 (fr)
WO (1) WO2014099256A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911488A1 (fr) * 2013-05-10 2014-11-13 The Procter & Gamble Company Produits de consommation comprenant des huiles modifiees silane
US10162141B1 (en) 2018-03-28 2018-12-25 Dow Global Technologies Llc Flooding composition with polysiloxane
US10150868B1 (en) 2018-03-28 2018-12-11 Dow Global Technologies Llc Flooding composition with polysiloxane
US12031020B2 (en) * 2018-07-03 2024-07-09 Dow Global Technologies Llc Olefin-based polymer compositions for flooring applications
WO2023196056A1 (fr) * 2022-04-07 2023-10-12 Dow Silicones Corporation Modificateur sensoriel non siloxane

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794718Q (fr) 1968-12-20 1973-05-16 Dow Corning Ltd Procede de reticulation d'olefines
JPS57207632A (en) * 1981-06-16 1982-12-20 Mitsubishi Petrochem Co Ltd Crosslinkable polyethylene resin composition
GB2124609B (en) * 1982-07-23 1986-05-29 Ici Plc Multi-component grouting system
US4834972A (en) * 1987-04-20 1989-05-30 Allied-Signal Inc. Gels of telomer-copolymers of ethylene and a silane
US5219560A (en) * 1989-03-20 1993-06-15 Kobayashi Kose Co., Ltd. Cosmetic composition
US4954335A (en) * 1989-05-31 1990-09-04 Helene Curtis, Inc. Clear conditioning composition and method to impart improved properties to the hair
US5272236A (en) 1991-10-15 1993-12-21 The Dow Chemical Company Elastic substantially linear olefin polymers
US5266627A (en) 1991-02-25 1993-11-30 Quantum Chemical Corporation Hydrolyzable silane copolymer compositions resistant to premature crosslinking and process
US5278272A (en) 1991-10-15 1994-01-11 The Dow Chemical Company Elastic substantialy linear olefin polymers
US5783638A (en) 1991-10-15 1998-07-21 The Dow Chemical Company Elastic substantially linear ethylene polymers
JP3145219B2 (ja) * 1992-12-01 2001-03-12 カネボウ株式会社 美爪料
JP3548179B2 (ja) * 1994-04-20 2004-07-28 ザ・ダウ・ケミカル・カンパニー シラン架橋性の実質的に線状であるエチレンポリマー類およびそれらの使用
US5824718A (en) 1995-04-20 1998-10-20 The Dow Chemical Company Silane-crosslinkable, substantially linear ethylene polymers and their uses
US6344218B1 (en) * 1998-11-23 2002-02-05 The Procter & Gamble Company Skin deodorizing and santizing compositions
US6531142B1 (en) * 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
FR2809010B1 (fr) * 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
ES2490990T3 (es) * 2005-07-11 2014-09-04 Dow Global Technologies Llc Composiciones que comprenden polímeros de olefina injertados con silano
US7863361B2 (en) 2005-11-15 2011-01-04 Momentive Performance Materials Inc. Swollen silicone composition, process of producing same and products thereof
EP1968534A2 (fr) 2005-12-20 2008-09-17 L'Oréal Kit comprenant une huile siliconee et des composes x et y silicones aptes a reagir ensemble sur les cils
BRPI0710672A2 (pt) * 2006-04-07 2011-08-16 Reckitt Benckiser artigo para cuidados pessoais
JP4772820B2 (ja) 2008-03-27 2011-09-14 三井化学株式会社 オレフィン系ワックス、ならびにシリコーン変性オレフィン系ワックス、これを用いたシリコーン系室温固化組成物、およびこれらを用いた化粧料
CA2774284C (fr) 2009-09-16 2017-11-28 Union Carbide Chemicals & Plastics Technology Llc Articles faconnes a l'etat fondu, reticules, et compositions pour les obtenir

Also Published As

Publication number Publication date
WO2014099256A3 (fr) 2014-12-31
US20160184210A1 (en) 2016-06-30
EP2934478A2 (fr) 2015-10-28
BR112015012520B8 (pt) 2020-03-24
CN105025877A (zh) 2015-11-04
US20190269599A1 (en) 2019-09-05
WO2014099256A2 (fr) 2014-06-26
JP2016504333A (ja) 2016-02-12
BR112015012520B1 (pt) 2020-03-03
JP6357484B2 (ja) 2018-07-11
CN105025877B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
US20190269599A1 (en) Silicon-containing polyolefins in personal care applications
US9999586B2 (en) Silicone modified polyolefins in personal care applications
US9181434B2 (en) Pituitous silicone fluids
US8017687B2 (en) Swollen silicone composition and process of producing same
US10172781B2 (en) Pituitous silicone fluid
US10940099B2 (en) Pituitous silicone emulsions
US9872828B2 (en) Emulsion of cross-linked aminosiloxane polymer
WO2020137913A1 (fr) Particules d'élastomère de silicone revêtues de résine de silicone, et leurs applications y compris dans des additifs pour résine organique
US20030203978A1 (en) Cosmetic compositions comprising silicone gels comprising entrapped, occluded or encapsulated pigments
JP7257147B2 (ja) 架橋ポリオルガノシロキサン及びそれを含むパーソナルケア組成物
CA2990162A1 (fr) Particules pourvues de revetements reticules pour applications cosmetiques
CA2990163A1 (fr) Procede de formation de particules avec des revetements reticules pour applications cosmetiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150521

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160725

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171002

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTG Intention to grant announced

Effective date: 20180209

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: MURGITROYD AND COMPANY, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 982753

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013035137

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180628

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180328

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180628

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180629

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 982753

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180730

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013035137

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20190103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181122

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191116

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131122

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180328

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180328

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180728

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20201111

Year of fee payment: 8

Ref country code: DE

Payment date: 20201110

Year of fee payment: 8

Ref country code: FR

Payment date: 20201013

Year of fee payment: 8

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602013035137

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20211122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211122

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211130